In the News

February 24, 2020
The Council applauds the FDA’s action and continues to call on policymakers to support legislation that would require all patents for the reference biologic to be listed in the Purple Book.
February 5, 2020
CMS’ proposal for a separate preferred specialty tier is a very welcome and significant step that will encourage greater generic and biosimilar adoption for America’s patients.
biologics market
February 3, 2020
The Biosimilars Council welcomes the FTC and FDA collaboration to promote competition in the biologics markets and bolster confidence in these medicines.
interchangeable insulin
January 28, 2020
The Biosimilars Council applauds the FDA for streamlining requirements for approval of biosimilar and interchangeable insulin based on sound science.
October 2, 2019
The Biosimilars Council applauds bipartisan efforts in the U.S. House of Representatives that would encourage biosimilar uptake and utilization by patients in the Medicare program by aligning patient, provider and taxpayer incentives.
September 17, 2019
Dear Chairman Alexander and Ranking Member Murray: On behalf of the undersigned organizations, we write to express urgent concern about a proposal in the President’s budget request that would undermine trust in the quality of biologic medicines.

Want to keep up to date with the biosimilars industry?

Sign up for Biosimilars Council Newsletter to hear about the field, learn about events, and find out how you can make an impact.